Prognostic Value of Circulating Tumor DNA in Pancreatic Cancer
British Journal of Cancer
The authors of this retrospective study evaluated the prognostic impact of KRAS-mutated circulating tumor DNA (ctDNA) in 105 patients with resectable pancreatic cancer who underwent pancreaticoduodenectomy. ctDNA was detected in 31/105 samples (31%). Median overall survival was 13.6 vs 27.6 months in ctDNA+ and ctDNA− groups, respectively (P <.0001).
circulating ctDNA in patients with resectable pancreatic cancer is a potential biomarker for poor prognosis
circulating tumor DNA in pts with resectable pancreatic cancer is a potential biomarker for poor prognosis Just think about it-The DNA of tumours is certainly not normal compared to its benign counterpart and we are increasingly seeing that this DNA can be shed in the course of the disease. We now are trying to nail down for each cancer if they do it, what is the lowest detectable threshold they do it at and what is the clinical impact of catching it “early” or never seeing it at all. The work is being done and it is one more example of precision mdeicine being built on the shoulders of basic science and smart questions with new tools